For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Crescendo Biologics Limited

USPTO Granted Patents = 21

EPO Patents = 6

Trademarks = 4

Forward Citations = 130

Loading Chart...

Loading Chart...

33 inventors (with patents filed for the assignee):

Yumin Teng (8 out of 9 patents)

Brian Timothy McGuinness (8 out of 24 patents)

Thomas Sandal (7 out of 7 patents)

4. James Legg (5 out of 5 patents)

5. Mike Romanos (5 out of 6 patents)

6. Carolyn Edwards (4 out of 4 patents)

7. Colette Johnston (4 out of 4 patents)

8. Christine Rossant (4 out of 4 patents)

9. Ulla Lashmar (4 out of 4 patents)

10. Bryan Edwards (4 out of 4 patents)

11. Nikki Royle (3 out of 3 patents)

12. Martyna Lewandowska (3 out of 3 patents)

13. Isabelle Osuch (3 out of 3 patents)

14. Chris Rossant (3 out of 3 patents)

15. Lorraine Thompson (3 out of 3 patents)

21 patents: Sort by Forward Citations

1. 12134643 - Compositions for treatment of disorders (2024-11-05),

2. 12077595 - Single domain antibodies that bind to CD137 (2024-09-03),

3. 11951172 - Therapeutic molecules that bind to LAG3 and PD1 (2024-04-09),

4. 11866510 - Chimeric antigen receptor with single domain antibody (2024-01-09),

5. 11814429 - Single domain antibodies to programmed cell death (PD-1) (2023-11-14),

6. 11746158 - Therapeutic molecules (2023-09-05),

7. 11667705 - IL-17A binding proteins (2023-06-06),

8. 11591398 - Single domain antibodies to programmed cell death protein 1 (PD-1) (2023-02-28),

9. 11401342 - Therapeutic molecules binding PSMA (2022-08-02),

10. 11312771 - Single-domain antibodies to programmed cell death 1 protein (PD-1), encoding nucleic acids and methods of using same (2022-04-26),

11. 11236174 - Therapeutic molecules (2022-02-01),

12. 10975161 - Molecules that bind prostate specific membrane antigen (PSMA) (2021-04-13),

13. 10947308 - Composition for treatment of disorders (2021-03-16),

14. 10654924 - IL-17A binding proteins (2020-05-19),

15. 10400030 - Methods for producing optimised therapeutic molecules (2019-09-03),

Crescendo Biologics Limited is a biopharmaceutical company focused on developing innovative T-cell engaging therapeutics for the treatment of cancer. They utilize their unique and proprietary biologics platform, Humabody, to generate fully human VH domain antibodies with superior specificity, efficacy, and drug-like properties. Crescendo Biologics aims to revolutionize cancer treatment by delivering next-generation solutions that target and destroy tumor cells through T-cell redirection and immune modulation.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

21 Patents

#46 in Cambridge

#842 in United Kingdom

#29,081 in the World

Cambridge, United Kingdom

Crescendo Biologics Limited

Forward Citations = 130

33 inventors:

Yumin Teng (8 out of 9 patents)

Brian Timothy McGuinness (8 out of 24 patents)

Thomas Sandal (7 out of 7 patents)

4. James Legg (5 out of 5 patents)

5. Mike Romanos (5 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…